206 related articles for article (PubMed ID: 34750990)
21. Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety.
Minichmayr IK; Karlsson MO; Jönsson S
Pharm Res; 2021 Apr; 38(4):593-605. PubMed ID: 33733372
[TBL] [Abstract][Full Text] [Related]
22. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
24. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
[TBL] [Abstract][Full Text] [Related]
25. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
[TBL] [Abstract][Full Text] [Related]
27. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
28. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Karas S; Etheridge AS; Nickerson DA; Cox NJ; Mohlke KL; Cecchin E; Toffoli G; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
Br J Cancer; 2022 Mar; 126(4):640-651. PubMed ID: 34703007
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.
Adiwijaya BS; Kim J; Lang I; Csõszi T; Cubillo A; Chen JS; Wong M; Park JO; Kim JS; Rau KM; Melichar B; Gallego JB; Fitzgerald J; Belanger B; Molnar I; Ma WW
Clin Pharmacol Ther; 2017 Dec; 102(6):997-1005. PubMed ID: 28445610
[TBL] [Abstract][Full Text] [Related]
30. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
31. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan.
Su YY; Chiang NJ; Chang JS; Wang YW; Shen BN; Li YJ; Hwang DY; Shan YS; Chen LT
ESMO Open; 2023 Feb; 8(1):100746. PubMed ID: 36527823
[TBL] [Abstract][Full Text] [Related]
32. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Dayyani F; Macarulla T; Johnson A; Wainberg ZA
Cancer Treat Rev; 2023 Feb; 113():102502. PubMed ID: 36641880
[TBL] [Abstract][Full Text] [Related]
33. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
[TBL] [Abstract][Full Text] [Related]
34. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
J Pharmacol Sci; 2019 May; 140(1):20-25. PubMed ID: 31105026
[TBL] [Abstract][Full Text] [Related]
35. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
[TBL] [Abstract][Full Text] [Related]
36. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
[TBL] [Abstract][Full Text] [Related]
37. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
[TBL] [Abstract][Full Text] [Related]
38. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Yang Y; Zhou M; Hu M; Cui Y; Zhong Q; Liang L; Huang F
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e479-e489. PubMed ID: 29932297
[TBL] [Abstract][Full Text] [Related]
39. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
